IL2 and neoplasm: The fusion of an anti-FAP antibody to IL2v allows for increased localized IL2v exposure in FAP-positive tissues in the tumor microenvironment; however, free or unbound FAP-IL2v can still bind to IL2Rβγ in other tissues, causing IL2-related adverse effects (7).